Bayer’s Xofigo plus Xtandi extends OS in mCRPC with bone metastases

Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.
Becker's Spine Review

Mayo Clinic uses light-cured implant to treat bone metastases

Mayo Clinic in Jacksonville, Fla., offers a minimally invasive procedure to stabilize bones weakened by metastatic cancer, a technique available at few U.S. centers. The photodynamic bone ...
Cancer Therapy Advisor

Adding Radium-223 to Enzalutamide Improves OS in mCRPC With Bone Metastases

For patients with mCRPC with bone metastases, the addition of radium-223 to enzalutamide therapy is associated with improved overall survival.

Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant ...

Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...
EurekAlert!

An ECOG-ACRIN imaging study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring treatment response in patients with bone metastases

The FEATURE study provides the first prospective validation of FDG-PET/CT and PERCIST response criteria in patients presenting with bone-only or bone-dominant metastatic breast cancer, opening the ...